Last updated: 2026-09-06 07:47:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ligand Pharmaceuticals Inc. (LGND) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $286,26, with a market capitalization of $5,69B and a P/E ratio of 28,87. Over the past 52 weeks, its price has ranged from $161,82 to $326,63. This page covers its latest market performance, valuation, price trends and company information.
$5,69B | |
$287,41 | |
$326,63 | |
$6,60 | |
$289,74 | |
97,08K | |
356,48K | |
28,87 | |
$326,63 | |
$161,82 | |
-- | |
-- |
Ligand Pharmaceuticals Inc. (LGND) last closed at $289,74 as of 2026-09-04 23:31:00, unchanged from the previous close of $289,74.
During the latest regular trading session, LGND traded between $6,60 and $326,63, with a volume of 97,08K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Ligand Pharmaceuticals Inc. (LGND) moved from $284,52 to $286,26, representing a gain of 0,61% ($1,74).
The stock traded between $275,60 and $291,14 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 176,50 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 75,5%
LGND is currently trading at $286,26, placing it 75,5% of the way from its 52-week low of $161,82 to its 52-week high of $326,63. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 47 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ligand Pharmaceuticals Inc. (LGND) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.